Patents by Inventor Brian R. Boettcher

Brian R. Boettcher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180369332
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Patent number: 10076554
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: September 18, 2018
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari Lynn Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20170166621
    Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Application
    Filed: August 26, 2016
    Publication date: June 15, 2017
    Applicant: NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari Lynn CAPLAN, Susan E. CELLITTI, Douglas S. DANIELS, Norio HAMAMATSU, Bernhard Hubert GEIERSTANGER, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Patent number: 9458214
    Abstract: The present invention relates to dual function fusions proteins comprising fibroblast growth factor 21 (FGF21) and Exenatide, Exendin-4, or GLP-1. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: October 4, 2016
    Assignee: NOVARTIS AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon, Susan E. Cellitti, Bernhard Hubert Geierstranger, Andreas Loew
  • Publication number: 20160051628
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 25, 2016
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Andreas LOEW, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Stephen Craig WELDON
  • Patent number: 9266935
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: February 23, 2016
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20150166622
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: February 24, 2015
    Publication date: June 18, 2015
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Patent number: 9023791
    Abstract: The present invention provides novel polypeptide and protein variants of fibroblast growth factor 21 (FGF21) and pharmaceutical compositions comprising FGF21 polypeptide and protein variants.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: May 5, 2015
    Assignees: Novartis AG, IRM LLC
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Bernhard H. Geierstanger, Norio Hamamatsu, Stuart Licht, Andreas Loew, Stephen Craig Weldon
  • Patent number: 9006400
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Grant
    Filed: September 25, 2012
    Date of Patent: April 14, 2015
    Assignee: Novartis AG
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20130079500
    Abstract: The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: September 25, 2012
    Publication date: March 28, 2013
    Inventors: Brian R. Boettcher, Shari L. Caplan, Douglas S. Daniels, Norio Hamamatsu, Stuart Licht, Stephen Craig Weldon
  • Publication number: 20120129766
    Abstract: The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Brian R. BOETTCHER, Shari L. CAPLAN, Douglas S. DANIELS, Bernhard H. GEIERSTANGER, Norio HAMAMATSU, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
  • Patent number: 6608038
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: August 19, 2003
    Assignee: Novartis AG
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai
  • Publication number: 20020065239
    Abstract: Disclosed are methods and compositions for treatment of diabetes, obesity and diabetic-related conditions. The methods include gene therapy based administration of a therapeutically effective amount of vectors encoding the following: glucokinase regulatory protein alone or co-administered with glucokinase or with metabolism modifying proteins; glucokinase co-administered with metabolism modifying proteins; or glucokinase regulatory protein co-administered with glucokinase in combination with metabolism modifying proteins, to a diabetic patient. Wherein the metabolism modifying proteins include UCP2, UCP3, PPAR&agr;, OB-Rb, GLP-1 and GLP-1 analogs (administered via vector or directly as a peptide). Preferred examples of GLP-1 analogs include GLP-1-Gly8, Extendin-4 and the “Black Widow” chimeric GLP-1 analog. Additionally, PPAR&agr; ligands and DPP-IV inhibitors may be co-administered with the above.
    Type: Application
    Filed: March 14, 2001
    Publication date: May 30, 2002
    Inventors: Shari L. Caplan, Brian R. Boettcher, Eric D. Slosberg, Sheila Connelly, Michael Kaleko, Urvi J. Desai